JP2011004758A5 - - Google Patents

Download PDF

Info

Publication number
JP2011004758A5
JP2011004758A5 JP2010183075A JP2010183075A JP2011004758A5 JP 2011004758 A5 JP2011004758 A5 JP 2011004758A5 JP 2010183075 A JP2010183075 A JP 2010183075A JP 2010183075 A JP2010183075 A JP 2010183075A JP 2011004758 A5 JP2011004758 A5 JP 2011004758A5
Authority
JP
Japan
Prior art keywords
antibodies
column
chimeric
mutations
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010183075A
Other languages
English (en)
Japanese (ja)
Other versions
JP5238000B2 (ja
JP2011004758A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011004758A publication Critical patent/JP2011004758A/ja
Publication of JP2011004758A5 publication Critical patent/JP2011004758A5/ja
Application granted granted Critical
Publication of JP5238000B2 publication Critical patent/JP5238000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010183075A 2007-08-09 2010-08-18 抗ｃｄ３７抗体 Active JP5238000B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114128.7 2007-08-09
EP07114128 2007-08-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010519473A Division JP5325216B2 (ja) 2007-08-09 2008-08-08 抗ｃｄ３７抗体

Publications (3)

Publication Number Publication Date
JP2011004758A JP2011004758A (ja) 2011-01-13
JP2011004758A5 true JP2011004758A5 (enExample) 2011-10-06
JP5238000B2 JP5238000B2 (ja) 2013-07-17

Family

ID=38925567

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010519473A Active JP5325216B2 (ja) 2007-08-09 2008-08-08 抗ｃｄ３７抗体
JP2010183075A Active JP5238000B2 (ja) 2007-08-09 2010-08-18 抗ｃｄ３７抗体
JP2013150731A Withdrawn JP2014039541A (ja) 2007-08-09 2013-07-19 抗ｃｄ３７抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010519473A Active JP5325216B2 (ja) 2007-08-09 2008-08-08 抗ｃｄ３７抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013150731A Withdrawn JP2014039541A (ja) 2007-08-09 2013-07-19 抗ｃｄ３７抗体

Country Status (37)

Country Link
US (7) US20100189722A1 (enExample)
EP (3) EP2241577A1 (enExample)
JP (3) JP5325216B2 (enExample)
KR (1) KR101593403B1 (enExample)
CN (4) CN105273086A (enExample)
AR (2) AR071242A1 (enExample)
AU (1) AU2008285590B2 (enExample)
BR (2) BRPI0815369A2 (enExample)
CA (1) CA2693464C (enExample)
CL (3) CL2008002349A1 (enExample)
CO (1) CO6251371A2 (enExample)
CY (1) CY1117101T1 (enExample)
DK (1) DK2178915T3 (enExample)
EA (2) EA027499B1 (enExample)
EC (2) ECSP109946A (enExample)
ES (1) ES2555202T3 (enExample)
HK (1) HK1220708A1 (enExample)
HR (1) HRP20160009T1 (enExample)
HU (1) HUE026221T2 (enExample)
IL (1) IL202645A (enExample)
MA (1) MA32665B1 (enExample)
ME (1) ME02300B (enExample)
MY (1) MY157555A (enExample)
NZ (2) NZ600022A (enExample)
PE (3) PE20090499A1 (enExample)
PH (1) PH12014501812A1 (enExample)
PL (1) PL2178915T3 (enExample)
PT (1) PT2178915E (enExample)
RS (1) RS54359B1 (enExample)
SG (1) SG190657A1 (enExample)
SI (1) SI2178915T1 (enExample)
TN (1) TN2010000068A1 (enExample)
TW (2) TWI535733B (enExample)
UA (2) UA105445C2 (enExample)
UY (1) UY31275A1 (enExample)
WO (1) WO2009019312A2 (enExample)
ZA (1) ZA200908758B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
LT2544719T (lt) * 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20120107317A1 (en) * 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
AU2012236210B2 (en) 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
EP3272364B1 (en) * 2011-12-13 2020-07-29 Nordic Nanovector ASA Chimeric therapeutic anti-cd37 antibodie hh1
RU2014140119A (ru) * 2012-03-30 2016-05-27 Иммьюноджен, Инк. Способы повышения эффективности терапии на основе cd37
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171289A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
US8992915B2 (en) * 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
EP2852388A4 (en) * 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
WO2014198330A1 (en) * 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with chlorambucil
AR097161A1 (es) 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
US9291244B2 (en) 2014-01-17 2016-03-22 Ford Global Technologies, Llc Nine speed automatic transmission
EP2966085A1 (en) 2014-07-11 2016-01-13 Boehringer Ingelheim International GmbH Antibody IgG1 with a modified heavy chain constant region
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
BR112017026027A2 (pt) 2015-06-08 2018-08-14 Debiopharm Int Sa combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
ES2699526T3 (es) * 2015-07-28 2019-02-11 Hoffmann La Roche Prueba de endotoxinas bacterianas mejorada para la determinación de endotoxinas
JP6890581B2 (ja) 2015-08-28 2021-06-18 デビオファーム インターナショナル， エス． アー． Ｃｄ３７の検出のための抗体およびアッセイ
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
IL307242B1 (en) * 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
EP3595721B1 (en) 2017-03-16 2025-07-09 The General Hospital Corporation Chimeric antigen receptors targeting cd37
CN119285787A (zh) 2017-03-31 2025-01-10 健玛保控股有限公司 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
WO2019006034A1 (en) * 2017-06-27 2019-01-03 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
CA3099928A1 (en) * 2018-06-22 2019-12-26 The General Hospital Corporation Chimeric antigen receptors targeting cd37 and cd19
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
AU2019354105A1 (en) 2018-10-04 2021-04-29 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN114650867A (zh) * 2019-08-30 2022-06-21 齐鲁普吉湾生物治疗公司 抗cd20抗体、抗cd37抗体及它们的混合物
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
EP4420683A1 (en) * 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
US20260191871A1 (en) * 2022-11-28 2026-07-09 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses
KR20260094403A (ko) 2023-10-18 2026-06-22 데비오팜 인터내셔널 에스에이 항-cd37 항체 메이탄신 접합체와 bcl2 저해제 또는 p13k 저해제를 포함하는 약물 조합
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
ES2146572T3 (es) * 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2004016753A2 (en) 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR20060080535A (ko) 2003-05-14 2006-07-10 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
PE20090499A1 (es) * 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102159243B (zh) 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
AU2009313877A1 (en) 2008-11-13 2011-06-30 Emergent Product Development Seattle, Llc CD37 immunotherapeutic combination therapies and uses thereof
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171289A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with further agents
US8992915B2 (en) * 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
WO2014198330A1 (en) 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with chlorambucil

Similar Documents

Publication Publication Date Title
HRP20211343T1 (hr) Protutijela protiv dkk-1
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201491837A1 (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
JP2014012688A5 (enExample)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2019528240A5 (enExample)
NZ715896A (en) Humanized or chimeric cd3 antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2020129387A (ru) Антитела к pd-1 собак
PE20140196A1 (es) Anticuerpos anti-cd37
EP3839049A3 (en) Antibodies, variable domains & chains tailored for human use
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2012068540A3 (en) Neutralizing anti-ccl20 antibodies
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
EP4345163A3 (en) Genetic engineering of non-human animals for the production of chimeric antibodies
WO2013173496A3 (en) Cd33 antibodies and use of same to treat cancer
EA201291161A2 (ru) Связывающие csf1r антитела
AR083293A1 (es) Agentes de union a cd33
JP2013539361A5 (enExample)
GB2525568A (en) Single cell bar-coding for antibody discovery
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
HRP20161298T1 (hr) Novi antagonisti protutijela i njihovi fab fragmenti protiv gpvi i njihova uporaba
JP2013502204A5 (enExample)
WO2013183032A3 (en) Humanized anti-trka antibodies with amino acid substitutions